Sign inCreate account

Report workspace tools

NCT01590446COMPLETEDanonymous

A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

BMN 111, Normal Saline

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

BMN 111, Normal Saline

Source & freshness

Source record

NCT ID

NCT01590446

Original source

ClinicalTrials.gov

Source last updated

Jun 11, 2012

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01590446

Title

A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers

Sponsor

BioMarin Pharmaceutical

Status

COMPLETED

Phase

PHASE1

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BMN 111, Normal Saline

Target normalized

BMN 111, Normal Saline

Interventions

BMN 111, Normal Saline

Public preview

Source record

The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01590446

Status

COMPLETED

Phase

PHASE1

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 11, 2012
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01590446

Indication

Achondroplasia

Modality

small molecule

Target

BMN 111, Normal Saline

Intervention

BMN 111, Normal Saline

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.